What Do GSK (LSE:GSK) Oncology Wins Mean For Its Long Term Growth?

• GSK (LSE:GSK) reported new data showing its investigational ADC risvutatug rezetecan produced strong responses in relapsed small cell lung cancer.
• The US FDA approved GSK's Jemperli as the first immunotherapy for MSI-H/dMMR locally advanced rectal cancer.
• GSK's risvutatug rezetecan trial readout and the new Jemperli approval only tell part of the oncology story for investors. We have also flagged 3 warning signs for GSK.

Consider reviewing other healthcare stocks using AI in treatment and drug discovery alongside these GSK updates through 8 healthcare AI stocks.

GSK, a £74.3b pharmaceuticals group focused on vaccines and specialty medicines, relies on its oncology pipeline to reinforce its position in cancer treatment alongside broader vaccine and general medicine portfolios across the United Kingdom, the United States and other markets.

4 things going right for GSK that this headline doesn't cover.

How does risvutatug rezetecan change GSK’s oncology opportunity?

Risvutatug rezetecan delivered a 61% confirmed objective response rate at 8 mg/kg in relapsed extensive stage small cell lung cancer, compared with 32% at 6 mg/kg. That is an early stage data point, but it gives GSK a clearer case for its global phase III EMBOLD SCLC-301 trial and supports plans to explore B7-H3 targeting across multiple solid tumours.

What does the new Jemperli approval signal for GSK’s cancer portfolio?

The FDA decision makes Jemperli the first immunotherapy cleared for adults with MSI-H/dMMR locally advanced rectal cancer, based on phase II data showing sustained clinical complete responses over more than two years of follow up. For GSK, this widens the medicine’s reach beyond recurrent or metastatic settings and adds another approved product alongside its late stage oncology pipeline.

Does this oncology news change the GSK Narrative for investors?

The community Narrative already leans on oncology and long acting HIV as key levers, with antibody drug conjugates like Ris rez identified as important to future specialty medicines revenue and mix. These results, together with the rectal cancer indication for Jemperli, sit on the positive side of that thesis but still need to translate into durable, commercially meaningful uptake.

See how these catalysts shape GSK's path to a £21.73 fair value.

What is the single development to watch next after these GSK updates?

The clearest next test is the global phase III EMBOLD SCLC-301 readout, which is assessing risvutatug rezetecan at the 8 mg/kg dose in late line ES-SCLC. A robust efficacy and safety profile in that larger study would either support the current oncology driven Narrative or force investors to reassess how much weight to put on GSK’s ADC ambitions.

Add GSK to your Watchlist and get alerts as these catalysts play out.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com